10-Q: Koru Medical Systems Reports Q3 2026 Growth, Margin Expansion

Koru Medical Systems announced an 11.2% increase in Q3 net revenues to $11.6 million and a 20.5% rise in gross profit, driven by domestic core business growth and improved gross margins.

Summary

• Koru Medical Systems reported net revenues of $11.6 million for the third quarter of 2026, an 11.2% increase year-over-year, driven by domestic core business growth.
• Gross profit for the quarter rose 20.5% to $7.5 million, with gross margin improving to 65.2% from 60.2% in the prior year period.
• Operating expenses increased by 3.2% to $7.4 million, primarily due to higher research and development costs.
• The company reported a net income of $218,103 for the third quarter of 2026, a significant improvement from a net loss of $777,966 in the same period last year.
• For the nine months ended September 30, 2026, net revenues increased 17.0% to $35.4 million, while the net loss decreased by 84.4% to $336,526 compared to the prior year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth and improved gross margins, though net losses persist for the year-to-date period.

Positives

• Net revenues increased by 11.2% to $11.6 million in Q3 2026 compared to Q3 2025.
• Domestic core revenues saw a significant increase of 31.6% in Q3 2026.
• Gross profit increased by 20.5% to $7.5 million in Q3 2026.
• Gross margin improved to 65.2% in Q3 2026 from 60.2% in Q3 2025.
• Net income for Q3 2026 was $218,103, a substantial improvement from a net loss of $777,966 in Q3 2025.
• Year-to-date net revenues increased by 17.0% to $35.4 million.
• Year-to-date net loss decreased by 84.4% to $336,526.

Negatives

• International core revenues decreased by 16.5% in Q3 2026.
• Pharma services and clinical trials revenues decreased by 27.4% in Q3 2026.
• Operating expenses increased by 3.2% to $7.4 million in Q3 2026.
• Research and development expenses increased by 37.3% to $1.3 million in Q3 2026.
• The company reported a net loss of $336,526 for the nine months ended September 30, 2026.

Risks

• Uncertainties associated with inflation, tariffs, war, and other geopolitical conflicts.
• Fluctuations in customer ordering patterns and availability and costs of raw materials and labor.
• Compliance with FDA and foreign authority regulations and the outcome of regulatory audits.
• Introduction and adoption of competitive products.
• Reimbursement related risks and government regulation of the home health care industry.
• Availability of sufficient capital if or when needed.
• Dependence on key personnel.

Future Outlook

The company expects its cash on hand, cash flows from operations, and available credit facility to meet its requirements for the next twelve months. Future capital requirements may necessitate additional debt or equity financing, depending on sales growth, R&D spending, international expansion, new product introductions, market acceptance, and economic conditions.

Management Comments

• The Company ended the third quarter of 2026 with $11.6 million in net revenues; an 11.2% increase compared to $10.4 million in the same period last year.
• Revenues were driven by growth in our core domestic business of 31.6%, partially offset by decreases of 16.5% in our core international business and 27.4% in our pharma services and clinical trials business.
• Gross profit for the third quarter of 2026 was $7.5 million; a 20.5% increase compared to $6.3 million in the same period last year.
• Gross margin was 65.2% for the three months ended September 30, 2026, an increase from 60.2% in the prior year period.
• Operating expenses for the third quarter of 2026 were $7.4 million, an increase of 3.2% compared to $7.1 million for the same period last year, driven by an increase of $0.3 million in research and development expenses, partially offset by a decrease of $0.1 million in selling, general, and administrative expenses.

Industry Context

StockSavvy.ai notes that Koru Medical Systems operates in the specialized subcutaneous drug delivery market, facing competition and regulatory oversight. The reported revenue growth and margin improvement align with a general trend of increasing demand for advanced drug delivery solutions, particularly for chronic conditions like PIDD and CIDP.

Comparison to Industry Standards

• The gross margin of 65.2% for Q3 2026 is strong, particularly for a medical device company, suggesting efficient manufacturing and pricing power.
• The increase in R&D spending aligns with industry trends of continuous innovation in drug delivery systems.
• Competitors in the subcutaneous infusion market include companies like BD (Becton, Dickinson and Company) and Ypsomed, which also offer infusion pumps and related consumables. Koru's reported growth in domestic core business and market share gains suggest it is effectively competing in its primary market.
• The company's focus on immunoglobulin delivery for PIDD and CIDP addresses a growing therapeutic area within the broader biopharmaceutical market.

Management Changes

Legal Proceedings

• The Company is not presently a party to any litigation or other legal proceedings that is believed to be material to its financial condition.

Stakeholder Impact

• Shareholders: Improved financial performance in Q3 2026 with increased revenues and net income, and reduced year-to-date net loss, may positively impact shareholder value. However, the ongoing net loss for the year-to-date period and potential future capital raises could dilute existing shareholders.
• Employees: Increased R&D spending and headcount additions suggest investment in growth and potential for future opportunities. Stock-based compensation continues to be a significant component of employee compensation.
• Customers: Continued development of infusion solutions and focus on product quality benefit patients and healthcare providers.
• Creditors: The company has a revolving credit facility and term loan, with amendments extending maturities. The company expects its current liquidity to be sufficient for the next twelve months, which should provide comfort to creditors.

Next Steps

• Continue investing in research and development and manufacturing equipment.
• Focus on achieving operating efficiencies and maintaining product quality.
• Monitor and manage future capital requirements, potentially including additional debt or equity financing.
• Continue to evaluate potential tariff refunds and rebates.

Key Dates

Recommendation

The company shows positive revenue and gross margin trends in the current quarter, and a significant reduction in net loss year-to-date. However, the persistent net loss for the nine-month period, coupled with the need for potential future capital raises and the inherent risks in the medical device industry, warrant a cautious 'hold' rating until sustained profitability is demonstrated.

Keywords

subcutaneous infusion, drug delivery, syringe drivers, Primary Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, pharma services, clinical trials, medical devices